Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.

You may also be interested in...



Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis

A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.

Noven's Stavzor Final Approval Anticipated In Mid-2008 After FDA Offers “Tentative Approval”

Valproic acid delayed release capsules gain tentative clearance for manic episodes associated with bipolar disorder and multiple seizures, including epilepsy.

Abbott Partners With Solvay On Simcor Ahead Of Planned 2008 Launch

Solvay will provide sales support in the U.S. in addition to funding development and promotions for the Niaspan/simvastatin combination.

Related Content

Topics

UsernamePublicRestriction

Register

PS066775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel